Quarles L D, Dennis V W, Gitelman H J, Harrelson J M, Drezner M K
Department of Medicine, Duke University Medical Center, Durham, 27514, USA.
J Clin Invest. 1985 May;75(5):1441-7. doi: 10.1172/JCI111846.
Although aluminum excess is an apparent pathogenetic factor underlying osteomalacia in dialysis-treated patients with chronic renal failure, the mechanism by which aluminum impairs bone mineralization is unclear. However, the observation that aluminum is present at osteoid-bone interfaces in bone biopsies of affected patients suggests that its presence at calcification fronts disturbs the cellular and/or physiochemical processes underlying normal mineralization. Alternatively, aluminum at osteoid-bone interfaces may reflect deposition in preexistent osteomalacic bone without direct effects on the mineralization process. We investigated whether aluminum accumulates preferentially in osteomalacic bone and, if so, whether deposition of aluminum occurs at calcification fronts and specifically inhibits mineralization. Aluminum chloride (1 mg/kg) was administered intravenously three times per week for 3 wk to five normal and five vitamin D-deficient osteomalacic dogs. Before administration of aluminum the vitamin D-deficient dogs had biochemical and bone biopsy evidence of osteomalacia. Bone aluminum content in the osteomalacic dogs (15.1 +/- 2.2 micrograms/g) and the plasma aluminum concentration (10.4 +/- 2.1 micrograms/liter) were no different than those of normal dogs (10.5 +/- 3.5 micrograms/g and 11.9 +/- 1.2 microgram/liter, respectively). After the 3 wk of aluminum administration the plasma phosphorus, parathyroid hormone, and 25-hydroxyvitamin D concentrations were unchanged in normal and vitamin D-deficient dogs. Similarly, no alteration in bone histology occurred in either group. In contrast, bone aluminum content increased to a greater extent in the vitamin D-deficient dogs (390.3 +/- 24.3 micrograms/g) than in the normal dogs (73.6 +/- 10.6 micrograms/g). Moreover, aluminum localized at the osteoid-bone interfaces of the osteomalacic bone in the vitamin D-deficient dogs, covering 42.9 +/- 9.2% of the osteoid-bone surface. Further, in spite of continued aluminum chloride administration (1 mg/kg two times per week), vitamin D repletion of the vitamin D-deficient dogs for 11 wk resulted in normalization of their biochemistries. In addition, while normal dogs maintained normal bone histology during the period of continued aluminum administration, vitamin D repletion of the vitamin D-deficient dogs induced healing of their bones. Indeed, the appearance of aluminum in the cement lines of the healed bones indicated that mineralization had occurred at sites of prior aluminum deposition. These observations illustrate that aluminum deposition in osteomalacic bone may be a secondary event that does not influence bone mineralization. Thus, although aluminum may cause osteomalacia in chronic renal failure, its presence at mineralization fronts may not be the mechanism underlying this derangement.
尽管铝过量是慢性肾衰竭透析治疗患者骨软化症的一个明显致病因素,但铝损害骨矿化的机制尚不清楚。然而,在受影响患者的骨活检中观察到类骨质-骨界面存在铝,这表明其在钙化前沿的存在扰乱了正常矿化的细胞和/或物理化学过程。或者,类骨质-骨界面的铝可能反映了在先前存在的骨软化骨中的沉积,而对矿化过程没有直接影响。我们研究了铝是否优先在骨软化骨中蓄积,如果是,铝的沉积是否发生在钙化前沿并特异性抑制矿化。每周静脉注射三次氯化铝(1mg/kg),持续3周,用于五只正常和五只维生素D缺乏的骨软化犬。在给予铝之前,维生素D缺乏的犬有骨软化的生化和骨活检证据。骨软化犬的骨铝含量(15.1±2.2μg/g)和血浆铝浓度(10.4±2.1μg/L)与正常犬(分别为10.5±3.5μg/g和11.9±1.2μg/L)无差异。给予铝3周后,正常犬和维生素D缺乏犬的血浆磷、甲状旁腺激素和25-羟基维生素D浓度均未改变。同样,两组的骨组织学均无改变。相比之下,维生素D缺乏犬的骨铝含量(390.3±24.3μg/g)比正常犬(73.6±10.6μg/g)增加得更多。此外,铝定位于维生素D缺乏犬骨软化骨的类骨质-骨界面,覆盖类骨质-骨表面的42.9±9.2%。此外,尽管继续给予氯化铝(1mg/kg,每周两次),对维生素D缺乏的犬补充维生素D 11周后其生化指标恢复正常。此外,在持续给予铝的期间,正常犬保持正常的骨组织学,而对维生素D缺乏的犬补充维生素D可诱导其骨愈合。事实上,愈合骨的黏合线中出现铝表明矿化发生在先前铝沉积的部位。这些观察结果表明,铝在骨软化骨中的沉积可能是一个不影响骨矿化的继发事件。因此,尽管铝可能导致慢性肾衰竭中的骨软化症,但其在矿化前沿的存在可能不是这种紊乱的潜在机制。